ASH 2019 | Splicing modulator H3B-8800 in myeloid malignancies: phase 1 results
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a clinical trial of H3B-8800, a splicing modulator, in myeloid cancers (NCT02841540). This phase I, open-label, first-in-human study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of H3B-8800 in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up